The first global approval of sarilumab in Canada has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight.

In September 2017, sarilumab (Kavzara™) was also approved in Japan for the treatment of adult patients with rheumatoid arthritis who have had an inadequate response to conventional treatments[1].

This approval is in addition to those already granted earlier this year in the US and Europe.

For further information related to the first approval of sarilumab please visit Drugs, or to learn more about the overall development of sarilumab across all indications visit AdisInsight.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.